1. Introduction {#sec1-ijms-17-01028}
===============

Neuroactive steroids, which are mainly synthesized by glial cells, exert peculiar actions to influence the development and function of the nervous system through both genomic and non-genomic mechanisms \[[@B1-ijms-17-01028],[@B2-ijms-17-01028]\]. The classic genomic action involves steroid binding to intracellular receptors and the regulation of protein translation \[[@B3-ijms-17-01028]\]. Neuroactive steroids can also show rapid effects, occurring within seconds to minutes, via the activation of membrane neurotransmitter receptors. It has been shown that neuroactive steroids determine the allosteric modulations on ligand-gated channels, including type-A γ-aminobutyric acid (GABA), *N*-methyl-[d]{.smallcaps}-aspartate (NMDA), and nicotinic receptors \[[@B1-ijms-17-01028],[@B4-ijms-17-01028],[@B5-ijms-17-01028],[@B6-ijms-17-01028],[@B7-ijms-17-01028],[@B8-ijms-17-01028],[@B9-ijms-17-01028],[@B10-ijms-17-01028],[@B11-ijms-17-01028]\]. These different interactions lead to the multiple actions of neuroactive steroids, affecting both glia and neurons in a concerted manner \[[@B12-ijms-17-01028]\]. For instance, oestrogens act as transcriptional regulators to modulate the synthesis of various proteins and growth factors in astrocytes \[[@B13-ijms-17-01028],[@B14-ijms-17-01028],[@B15-ijms-17-01028],[@B16-ijms-17-01028],[@B17-ijms-17-01028],[@B18-ijms-17-01028],[@B19-ijms-17-01028],[@B20-ijms-17-01028],[@B21-ijms-17-01028],[@B22-ijms-17-01028],[@B23-ijms-17-01028],[@B24-ijms-17-01028],[@B25-ijms-17-01028]\]. Interestingly, oestrogens increase glutamate transporter expression in astrocytes via the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and the cAMP response element binding protein (CREB) pathways \[[@B26-ijms-17-01028]\]. Among the actions exerted by steroids, the increase in the expression of the mitochondria-encoded subunits of the respiratory chain influences the mitochondrial respiratory function, and this activity may be of particular interest for enhancing the functional efficiency of astrocytes \[[@B27-ijms-17-01028],[@B28-ijms-17-01028]\].

Notably, bidirectional glia-neuron communication was suggested by several scientific reports showing that glial cells and neurons can respond to the same signals and that they can mutually modulate the cellular response (for a review see \[[@B12-ijms-17-01028]\]). For this reason, glial cell well-being is of particular importance for the efficiency of the whole brain.

Translocator protein 18 kDa (TSPO), which is primarily located in the outer mitochondrial membrane, is highly expressed in steroid-synthesizing tissues, including glial cells. Although few reports questioned the role of TSPO in steroidogenesis \[[@B29-ijms-17-01028],[@B30-ijms-17-01028],[@B31-ijms-17-01028]\], most studies, including the most recent ones, propose that TSPO is an important protein for steroid synthesis \[[@B32-ijms-17-01028],[@B33-ijms-17-01028],[@B34-ijms-17-01028]\]. TSPO binds cholesterol with high affinity and, in a combined action with the steroidogenic acute regulatory protein (StAR), allows cholesterol to translocate into mitochondria, which represents the rate-limiting step of steroidogenesis \[[@B35-ijms-17-01028],[@B36-ijms-17-01028],[@B37-ijms-17-01028]\]. The steroid biosynthetic pathway is triggered by the cleavage of the cholesterol aliphatic side chain, which is catalyzed by the cytochrome P450 side chain cleavage (P450scc) enzyme, producing pregnenolone. Then, pregnenolone is converted to other neurosteroids by enzymes located in the endoplasmic reticulum, such as hydroxysteroid dehydrogenases \[[@B38-ijms-17-01028],[@B39-ijms-17-01028]\].

A number of TSPO-targeted molecules have been reported as neuroprotective, anti-inflammatory, and regenerating agents in different in vitro and in vivo models, suggesting their possible development as effective therapeutic tools (for a review see \[[@B40-ijms-17-01028]\]). For instance, in gliosis, TSPO ligands were able to decrease reactive gliosis and prevent neuronal loss \[[@B41-ijms-17-01028],[@B42-ijms-17-01028]\]. The stimulation of neurosteroidogenesis has been hypothesized as the basis for the positive actions of the TSPO ligand \[[@B43-ijms-17-01028]\], and, for these reasons, TSPO ligands are currently under investigation as therapeutic tools to preserve a functional brain environment and the glia-neuron bidirectional interactions \[[@B44-ijms-17-01028]\]. Very recently, we have found that the *N*,*N*-dialkyl-2-phenylindol-3-ylglyoxylamide class (PIGAs) of TSPO ligands reduces oxidative stress and the activity of pro-inflammatory enzymes in rat glial cells through the de novo neurosteroid synthesis \[[@B45-ijms-17-01028]\].

Based on the previously described pro-survival activity of TSPO ligands in neurons and glia, in the present work, the effects of the TSPO ligands on astrocyte well-being were assessed by focusing on the involvement of steroidogenesis. Therefore, the residence time of some investigated ligands were also assessed because we have recently shown that the time over which a ligand interacts with TSPO directly affects its steroidogenic efficacy \[[@B46-ijms-17-01028]\]. The human glioblastoma--astrocytoma cell line U87MG and normal human astrocytes were used as cellular models. U87MG cells express the astrocyte cell marker glial fibrillary acidic protein (GFAP) and are widely used as an in vitro astrocyte model \[[@B47-ijms-17-01028],[@B48-ijms-17-01028],[@B49-ijms-17-01028],[@B50-ijms-17-01028]\]. Recent data have shown comparable responses of U87MG cells and primary human astrocytes after inflammatory insult, highlighting the potential use of U87MG cells in drug discovery stages, as it is not feasible to screen compounds in primary human cells \[[@B50-ijms-17-01028]\]. However, data from healthy human astrocytes were crucial for validating TSPO activity under normal conditions. Thus, 13 high affinity, selective TSPO ligands belonging to our previously described PIGA class \[[@B51-ijms-17-01028],[@B52-ijms-17-01028]\] were selected and evaluated for their ability to increase the Oxidative Metabolism Activity/Proliferation index in human astrocyte models. The most promising compounds were then assessed for their steroidogenic activity and residence time. Finally, the relation between oxidative metabolism, proliferation activity, and the induction of neurosteroidogenesis was investigated.

2. Results {#sec2-ijms-17-01028}
==========

2.1. N,N-Dialkyl-2-phenylindol-3-ylglyoxylamide (PIGA) Ligands Increase the Oxidative Metabolism Activity/Proliferation Index in a Human Astrocyte Model {#sec2dot1-ijms-17-01028}
--------------------------------------------------------------------------------------------------------------------------------------------------------

TSPO expression has previously been established in U87MG cells \[[@B53-ijms-17-01028]\]. To assess the potential effects of the PIGA ligands on the activation of oxidative metabolism, U87MG cells were cultured under serum-reduced growth conditions; serum starvation is a well-known method to arrest the cells in a basal metabolic state (G0/G1 phase) \[[@B54-ijms-17-01028],[@B55-ijms-17-01028]\]. The metabolic activity of the astrocyte models was estimated using the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenol)-2-(4-sulfophenyl)-2*H*-tetrazolium, inner salt) (MTS) assay \[[@B56-ijms-17-01028]\]. This tetrazolium dye can be reduced by the metabolic reducing agents NADH and NADPH to a water-soluble formazan salt; the amount of produced formazan has been considered a marker of the Oxidative Metabolic Activity index \[[@B57-ijms-17-01028]\]. The redox reactions can occur in both the mitochondria and cytosol; in particular, it has been shown that tetrazolium reduction mainly reflects cytosolic redox activity in astroglia and is dependent on glyceraldehyde-3-phosphate dehydrogenase activity \[[@B56-ijms-17-01028]\]. Furthermore, as the reduction of the tetrazolium compound can only be achieved in viable cells, the tetrazolium assay has also been widely used for the quantitative assessment of cellular proliferation for over three decades \[[@B56-ijms-17-01028],[@B57-ijms-17-01028]\].

The effects of PIGAs and the TSPO reference standard ligand PK11195 (ranging from nanomolar to micromolar concentrations) on the Oxidative Metabolism Activity/Proliferation (OMAP) index in U87MG cells were evaluated after 48 h of incubation. The derivatives PIGA1128, PIGA1130, PIGA1136, PIGA1137, PIGA1138, PIGA1165, PIGA1174, PIGA1175, and PIGA1212 significantly increased the OMAP index, with the maximal mean value (163%) observed for 1 µM PIGA1138 (*p* \< 0.001 vs. the control) ([Figure 1](#ijms-17-01028-f001){ref-type="fig"}).

The most promising derivatives were those featuring a 2-naphthyl substituent as an aryl group (PIGA1128, PIGA1136, PIGA1137, and PIGA1338; see [Table 1](#ijms-17-01028-t001){ref-type="table"} for the chemical structures). In particular, PIGA1136 and PIGA1138 yielded statistically significant results at all tested concentrations. PIGA1174 and PIGA1175 were significantly effective at 10 and 100 nM, the two lowest concentrations tested. Conversely, PIGA1128, PIGA1130, PIGA1137, and PIGA1165 were active at the higher doses of 100 nM and 1 µM. Statistically significant results were not observed for PIGA1226, PIGA1228, PIGA1244, PIGA1248, and the reference compound PK11195. These results suggested that the TSPO ligands positively affected the well-being of an astrocytic cell line when the cells were maintained in a constrained low metabolic state.

2.2. PIGA Ligands Effectively Stimulate Steroidogenesis in Vitro {#sec2dot2-ijms-17-01028}
----------------------------------------------------------------

To assess the ability of PIGA ligands to stimulate steroidogenesis in vitro, the synthesis of the first steroid metabolite pregnenolone was evaluated in the presence of inhibitors of pregnenolone metabolism. As a first step, the assessment was performed in a rat C6 cell line, the glial cell model that is conventionally used to measure mitochondrial receptor-regulated steroidogenesis \[[@B58-ijms-17-01028]\]. The amount of pregnenolone released from the C6 cells was measured after a 2 h incubation with a fixed concentration of the most promising PIGAs in terms of metabolic activation (PIGA1128, PIGA1130, PIGA1136, PIGA1137, and PIGA1138).

The obtained results showed that all PIGA derivatives significantly increased pregnenolone synthesis in the C6 cells compared to the control (cells treated with DMSO and set to 100%) ([Figure 2](#ijms-17-01028-f002){ref-type="fig"}A and [Table 2](#ijms-17-01028-t002){ref-type="table"}). The highest pregnenolone level was observed after the C6 cells were treated with PIGA1137 and PIGA1138 (increase in pregnenolone synthesis of 208% and 215%, respectively, *p* \< 0.001) ([Figure 2](#ijms-17-01028-f002){ref-type="fig"}A and [Table 2](#ijms-17-01028-t002){ref-type="table"}).

To explore whether the promising steroidogenic effects of the PIGA ligands were maintained in a human astrocytic model, the pregnenolone assessment was performed in U87MG cells. As shown in [Figure 2](#ijms-17-01028-f002){ref-type="fig"}B and [Table 2](#ijms-17-01028-t002){ref-type="table"}, the PIGA ligands also significantly induced steroidogenesis in the U87MG cells, and the results were comparable to those obtained in the C6 cells. The best performing derivatives were PIGA1137 and PIGA1138, showing an increase in pregnenolone synthesis of 288% and 299%, respectively (*p* \< 0.001; [Figure 2](#ijms-17-01028-f002){ref-type="fig"}B and [Table 2](#ijms-17-01028-t002){ref-type="table"}). Notably, these two PIGA ligands also presented the best metabolic activation profile in the U87MG cells. The standard PK11195 similarly increased pregnenolone production in the C6 and U87MG cells (139% and 144%, respectively, *p* \< 0.01) ([Figure 2](#ijms-17-01028-f002){ref-type="fig"}).

2.3. The Best Performing PIGA Ligands in Terms of Steroidogenesis Stimulation Are Characterized by a Long Residence Time {#sec2dot3-ijms-17-01028}
------------------------------------------------------------------------------------------------------------------------

Our very recent results have shown that the time over which a ligand interacts with TSPO directly affects its steroidogenic efficacy \[[@B46-ijms-17-01028]\]. The time of the ligand-target interaction is a kinetic parameter known as Residence Time (RT), and it is calculated by the reciprocal of the dissociation rate constant (*k*~off~). For unlabelled TSPO ligands, *k*~off~ is experimentally derived by the competition kinetic association assay \[[@B46-ijms-17-01028]\]. The RT values of the most promising compounds were evaluated to relate the TSPO kinetic binding parameters and steroidogenic activity of the PIGA ligands. Consistent with our previous results, the 2-naphthyl derivative PIGA1138, which is characterized by a long RT (141 min) \[[@B46-ijms-17-01028]\], was the best performing ligand in terms of its ability to stimulate steroidogenesis in both the C6 and U87MG cells. In contrast, the standard PK11195, which is characterized by a short RT (33 min) \[[@B46-ijms-17-01028]\], showed a reduced ability to stimulate steroidogenesis compared to PIGA1138. The RT of PIGA1128 has been already determined (55 min) \[[@B46-ijms-17-01028]\]; as expected, it showed an intermediate ability to stimulate steroidogenesis. The RTs of additional 2-naphthyl derivatives with promising steroidogenic ability in human U87MG cells (PIGA1136 and PIGA1137) were here examined. Kinetic experiments showed that the association rate constant (*k*~on~), *k*~off~ and RT value for PIGA1136 were 2.52 × 10^7^ M^−1^·min^−1^, 0.0178 min^−1^ and 56 min, respectively. For PIGA1137, the *k*~on~, *k*~off~ and RT values were 3.56 × 10^7^ M^−1^·min^−1^, 0.0185 min^−1^ and 54 min, respectively. For PIGA1136 and PIGA1137, the kinetically derived *K*~d~ values (*k*~off~/*k*~on~) were 0.71 and 0.52 nM, respectively. These values were in good agreement with the previously reported *K*~i~ values \[[@B52-ijms-17-01028]\] obtained from competition binding experiments at equilibrium (the *K*~i~ values for PIGA1136 and PIGA1137 were 0.53 and 0.56 nM, respectively).

2.4. The Oxidative Metabolism Activity/Proliferation Index of PIGA1138 Is Related to Steroid Production {#sec2dot4-ijms-17-01028}
-------------------------------------------------------------------------------------------------------

The OMAP index and the percentage of pregnenolone production could not be directly compared, as they were obtained in different experimental settings. However, the correlation analyses indicated a strong relationship between these two parameters. Indeed, Spearman's correlation analysis of the OMAP index and pregnenolone production in U87MG cells treated with micromolar concentrations of the compounds revealed a highly significant *p* value (*p* = 0.0004, [Figure 3](#ijms-17-01028-f003){ref-type="fig"}).

To deeply investigate the correlation between the ability of the most promising PIGA ligands to promote astrocyte survival and their neurosteroidogenic activity, the ligand-mediated metabolic activation of U87MG cells was evaluated in the presence and absence of [dl]{.smallcaps}-aminoglutethimide (AMG), an inhibitor of cytochrome P450 side chain cleavage (P450scc), the enzyme that catalyzes the first step of steroidogenesis. The assay was performed for PIGA1138, which was selected as the most representative compound based on its ability to effectively increase both the OMAP index and pregnenolone production. The cells were maintained in a serum-reduced growth condition; in this basal metabolic state, AMG alone did not affect the OMAP index ([Figure 4](#ijms-17-01028-f004){ref-type="fig"}).

The results showed that PIGA1138 increased the OMAP index of the U87MG cells in a concentration-dependent manner and the effects were completely counteracted by the co-treatment with AMG ([Figure 4](#ijms-17-01028-f004){ref-type="fig"}), clearly supporting the hypothesis that the PIGA ligand-induced increase in the OMAP index was mainly related to steroid production.

2.5. PIGA1138 Promoted the Activation of Oxidative Metabolism in Normal Human Astrocytes {#sec2dot5-ijms-17-01028}
----------------------------------------------------------------------------------------

Although the U87MG cell line is widely used as an astrocyte model in vitro, we verified the consistency of the obtained data by evaluating the effects of PIGA1138 and PK11195 on healthy normal human astrocytes. As first step, the TSPO expression levels were quantified using \[^3^H\]PK11195 as a probe. In the whole membranes derived from normal human astrocytes, the \[^3^H\]PK11195 binding reached saturation, showing a maximal binding capacity of 9.548 fmol/mg. In terms of the equilibrium dissociation constant, the experimentally derived \[^3^H\]PK11195 binding affinity was 2.8 nM.

Then, the effects of PIGA1138 and PK11195 on healthy normal human astrocytes maintained under serum-reduced growth conditions were evaluated ([Figure 5](#ijms-17-01028-f005){ref-type="fig"}A). PK11195 did not increase the astrocytes' OMAP index. In contrast, PIGA1138 significantly promoted the astrocytes' well-being (*p* \< 0.001) ([Figure 5](#ijms-17-01028-f005){ref-type="fig"}A), in accordance with the data obtained in the U87MG cells ([Figure 1](#ijms-17-01028-f001){ref-type="fig"}).

Finally, to verify if the serum-reduced conditions used in the experiments could affect the obtained results, parallel cell cultures maintained under normal growth conditions (20% serum medium) were treated with ligand and assessed. As shown in [Figure 5](#ijms-17-01028-f005){ref-type="fig"}B, PIGA1138 also increased the astrocytes' OMAP index under the normal growth culture conditions, whereas PK11195 did not affect the astrocytes' well-being. The results obtained for PIGA1138 are in accordance with those obtained in astrocytes grown under serum-reduced conditions, suggesting that the increase in steroid production exerted a positive effect when the cells were maintained in a housekeeping metabolic state and promoted the general well-being of the astrocytes under normal growth conditions.

3. Discussion {#sec3-ijms-17-01028}
=============

In this study, TSPO PIGA ligand treatments showed a positive relation between steroidogenesis induction and the Oxidative Metabolism Activity/Proliferation Index in rat and human cell models. Notably, the data obtained in these astrocytic cell models were consistent with those acquired in healthy human astrocytes. Firstly, the ability of a number of PIGA ligands to stimulate the OMAP index was shown. Then, the ability of the ligands to induce steroidogenesis was evaluated and related with their TSPO residence time. It is likely that the metabolic stimulation was mediated by the modulation of steroid levels, as the positive effects of the compounds were completely counteracted by the treatment with the neurosteroid synthesis inhibitor AMG.

As previously reported in the nervous system, neuroactive steroids exert several direct regulatory activities on neurons and glial cells \[[@B59-ijms-17-01028],[@B60-ijms-17-01028],[@B61-ijms-17-01028],[@B62-ijms-17-01028],[@B63-ijms-17-01028],[@B64-ijms-17-01028],[@B65-ijms-17-01028],[@B66-ijms-17-01028]\]; the role of TSPO in the release of neurosteroids led us to investigate the relation among the TSPO compound binding ability, OMAP index, and neurosteroid release in rat and human astrocytes. We selected a number of previously reported PIGA ligands with high affinities towards TSPO. The PIGA-induced increase in the OMAP index showed a good agreement with previous data reporting that three different TSPO ligands (triakontatetraneuropeptide, octadecaneuropeptide and Ro5-4864), at low concentrations, induce a dose-dependent increase in DNA synthesis in rat primary astrocytes by activating TSPO \[[@B67-ijms-17-01028],[@B68-ijms-17-01028]\]. These results provide the evidence of a role for TSPO ligands in the control of glial cell proliferation. Indeed, although some forerunner studies have shown that low ligand concentrations inhibit astrocyte proliferation \[[@B69-ijms-17-01028],[@B70-ijms-17-01028]\], most studies have shown a proliferative role for TSPO ligands. For instance, TSPO-related proliferation has been evaluated in C6 glioma cells in serum-free medium, as well as in a standard fibroblast cell line, showing that nanomolar concentrations of PK11195 and Ro5-4864 increased the growth rate and \[^3^H\]thymidine incorporation \[[@B71-ijms-17-01028]\]. A significant increase in \[^3^H\]thymidine incorporation in human glioma cells following treatment with 10 nM PK11195 in serum-free media has been confirmed; the same study also showed an increase in mitochondrial mass and lipid fluidity \[[@B72-ijms-17-01028]\]. It has been suggested that the changes in mitochondrial lipid metabolism might lead to mitochondrial biogenesis to support the increased metabolic requirements for cell division \[[@B72-ijms-17-01028],[@B73-ijms-17-01028],[@B74-ijms-17-01028]\].

Concerning the well-known discrepancy between the functional efficacy and affinity of TSPO ligands \[[@B75-ijms-17-01028]\], the PIGA compounds used here presented different functional effects on astrocytes in terms of the OMAP index, despite their similar TSPO affinities. Interestingly, the PIGA compounds that were able to interact with TSPO for a longer time (high RT) also presented higher pregnenolone synthesis induction and promoted better astrocyte well-being, in accordance with our previous data suggesting that the residence time is a predictive parameter for estimating steroidogenic activity \[[@B46-ijms-17-01028]\]. Consistent with the present findings, it has been shown that primary astrocytes and C6 cells that were treated with nanomolar concentrations of PK11195 and Ro5-4864 exhibited an increase in the progesterone content in the medium that was 2--3-fold higher than the basal levels \[[@B76-ijms-17-01028]\]. Similarly, the TSPO ligand AC-5216 increased the allopregnanolone level in meningioma cells \[[@B77-ijms-17-01028]\], supporting the theory that TSPO ligands have a role in the regulation of steroid production. To our knowledge, this is the first study investigating steroidogenesis in a rat cellular model and in human glial cells in parallel, showing a good agreement between the data obtained in these two different cellular models.

Steroidogenesis stimulation is a widely proposed mechanism for the neuroprotective actions of TSPO ligands (for a review see \[[@B40-ijms-17-01028]\]). In this line, we have recently demonstrated the involvement of steroidogenesis in the pro-survival properties of the PIGA ligands against cytotoxic insults, such as lipid peroxidation (induced by cellular glutathione depletion) and inflammatory responses (induced by LPS/IFN-γ cell exposure) \[[@B45-ijms-17-01028]\]. Moreover, the PIGA-elicited modulation of the StAR protein levels has been recently demonstrated; in particular, we have shown that the stimulation of astroglial-derived cells with PIGAs leads to an increase of the 30 kDa intra-mitochondrial StAR, an indirect evidence of an increased cholesterol transfer into mitochondria \[[@B45-ijms-17-01028]\].

It is well known that the effects of steroids are mediated by changes in cellular metabolism \[[@B78-ijms-17-01028]\]. Here, we clearly showed that the positive effects of the PIGA ligands on the astrocytes were mediated by steroids, as they were completely prevented by the pre-treatment with the inhibitor of steroid synthesis, AMG. These data support the theory that the autocrine effects are due to neurosteroid release by the astrocytes themselves.

In conclusion, the importance of the induction of neurosteroidogenesis on astrocyte well-being was investigated in a human astrocyte model in vitro. Astrocytes play a pivotal role in the complex central nervous system network. The loss or the gain of astrocyte functions could be the basis of several pathological conditions \[[@B79-ijms-17-01028],[@B80-ijms-17-01028],[@B81-ijms-17-01028],[@B82-ijms-17-01028],[@B83-ijms-17-01028],[@B84-ijms-17-01028],[@B85-ijms-17-01028],[@B86-ijms-17-01028]\]. In this respect, the positive effects of TSPO-stimulated neurosteroid release on astrocytes well-being were demonstrated. The development of molecules able to stimulate steroid release could represent a therapeutic strategy for central nervous system diseases characterized by astrocyte loss. Furthermore, these ligands may be exploited as pharmacological tools to deeply investigate the autocrine/paracrine roles of neurosteroids in the control of astrocyte metabolism.

4. Experimental Section {#sec4-ijms-17-01028}
=======================

4.1. Materials {#sec4dot1-ijms-17-01028}
--------------

\[^3^H\] PK11195 (Specific Activity, 85.7 μCi/nmol) was obtained from Perkin-Elmer Life Sciences (Perkin Elmer Italia, Monza, Italy). PK11195 and the protease inhibitors were purchased from Sigma-Aldrich (Sigma-Aldrich S.r.l., Milan, Italy). Dulbecco's Modified Eagle's Medium, fetal bovine serum, [l]{.smallcaps}-glutamine, penicillin, and streptomycin were purchased from Lonza (Milan, Italy). The enzyme-linked immunosorbent assay (ELISA) used to measure the pregnenolone levels was obtained from IBL (Hamburg, Germany). SU10603 and trilostane were gifts from Novartis Farma (Varese, Italy) and Susanne Zister (University of Dublin, Dublin, Ireland), respectively. All other chemical reagents were obtained from commercial sources.

4.2. Drugs {#sec4dot2-ijms-17-01028}
----------

The compounds PIGA1228, PIGA1248, PIGA1175, PIGA1165, PIGA1174, PIGA1128, PIGA1136, PIGA1130, PIGA1137, PIGA1138, PIGA1226, PIGA1244, and PIGA1212 were synthesized according to the experimental procedure that we previously described \[[@B51-ijms-17-01028],[@B52-ijms-17-01028]\]. Briefly, the appropriate 2-arylindoles, which were commercially available or easily obtained with a one-step Fischer indole synthesis, were reacted with oxalyl chloride at room temperature in anhydrous diethyl ether to produce the corresponding 2-arylindolylglyoxylyl chlorides. These compounds were then treated with the appropriate dialkylamine in dry toluene solution in the presence of triethylamine at room temperature to yield the target PIGA ligands \[[@B51-ijms-17-01028],[@B52-ijms-17-01028]\].

4.3. Cell Culture {#sec4dot3-ijms-17-01028}
-----------------

U87MG cells were purchased from the National Institute for Cancer Research of Genoa (Genoa Italy) and cultured in RPMI supplemented with 10% fetal bovine serum (FBS), 2 mM [l]{.smallcaps}-glutamine, 1% non-essential amino acids, penicillin (100 U/mL) and streptomycin (100 mg/mL) at 37 °C in 5% CO~2~. C6 rat glioma cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS, 2 mM [l]{.smallcaps}-glutamine, penicillin (100 U/mL) and streptomycin (100 mg/mL) at 37 °C in 5% CO~2~. Human astrocytes were obtained from GIBCO (Life Technologies, Milan, Italy). Human astrocytes were cultured in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1% N-2 Supplement, penicillin (100 U/mL) and streptomycin (100 mg/mL) at 37 °C in 5% CO~2~.

4.4. The Oxidative Metabolism Activity/Proliferation Index in the Astrocyte Cell Models {#sec4dot4-ijms-17-01028}
---------------------------------------------------------------------------------------

Rat C6 cells, human U87MG cells or human primary astrocytes were seeded in 96-well plates (10,000 cells/well) and maintained in their specific, complete culture media for 24 h. Then, the culture media were refreshed with serum-reduced media (1% FBS). After 16 h, the cells were treated with increasing concentrations of the PIGA ligands (ranging from 10 nM to 1 µM) for 48 h. In the experiments used to evaluate the specific contribution of PIGA ligand-induced steroid production, the U87MG cells were pretreated (1 h before the addition of the PIGA ligands) with AMG (50 µM), a potent inhibitor of steroidogenesis. After 48 h, the MTS reagent was added to the PIGA ligand-treated cells, and the colorimetric MTS conversion was quantified after 2 h by measuring the absorbance at 490 nm with a microplate reader (WallacVictor 2, 1420 Multilabel Counter, Perkin Elmer, MA, USA).

4.5. Pregnenolone Quantification {#sec4dot5-ijms-17-01028}
--------------------------------

The amount of pregnenolone in the rat C6 and human U87MG astrocyte models were quantified as previously reported \[[@B46-ijms-17-01028]\]. Briefly, C6 or U87MG cells were incubated with 40 µM TSPO PIGA ligands in saline medium (140 mM NaCl, 5 mM KCl, 1.8 mM CaCl~2~, 1 mM MgSO~4~, 10 mM glucose, 10 mM *N*-2-hydroxyethylpiperazine-*N*′-2-ethanesulfonic acid (HEPES)--NaOH, pH 7.4, and 0.1% bovine serum albumin) containing the inhibitors of pregnenolone metabolism trilostane (25 μM) and SU10603 (10 μM). After 2 h of incubation, the conditioned salt medium was collected and the amount of pregnenolone secreted into the medium was quantified by an ELISA.

4.6. RT Determination of the TSPO PIGA Ligands {#sec4dot6-ijms-17-01028}
----------------------------------------------

The RT values of the TSPO PIGA ligands were calculated from the reciprocal of their dissociation rate constant (*k*~off~). The *k*~off~ values were assessed by the competition kinetic association assay, as previously reported \[[@B46-ijms-17-01028]\]. In particular, the TSPO-specific and TSPO-selective radioligand \[^3^H\]PK11195 (approximately 20 nM, specific activity of 21.4 μCi/nmol) and PIGA ligand were simultaneously added to the final reaction volume (500 µL) containing a rat kidney membrane homogenate (30 µg of proteins) and assay buffer (50 mM Tris-HCl, pH 7.4). The incubation of the samples was terminated at various times by vacuum filtration. The PIGA ligands were solubilized with DMSO and tested at a concentration corresponding to a three-fold higher value than the respective value of the inhibition constant (*K*~i~). The *K*~i~ values have been reported previously \[[@B52-ijms-17-01028]\]. The nonspecific binding was determined in the presence of 1 µM PK11195. The experimentally derived data were analyzed using the "kinetics of competitive binding" using Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA).

4.7. Radiolabel Binding Experiment in Human Astrocytes Using \[^3^H\] PK11195 {#sec4dot7-ijms-17-01028}
-----------------------------------------------------------------------------

For crude membranes, confluent human astrocytes derived from a 175 cm^2^ cell flask were harvested using phosphate-buffered saline (PBS), pH 7.4, supplemented with EDTA 0.04%. After the cells were collected by centrifugation (200× *g* for 5 min), the pellet was suspended in 10 mL of ice-cold buffer (5 mM Tris--HCl, pH 7.4 containing protease inhibitors (160 μg/mL benzamidine, 200 μg/mL bacitracin and 20 μg/mL trypsin inhibitor)) and homogenized with an Ultraturrax. Then, the homogenate was centrifuged at 48,000× *g* for 15 min at 4 °C and the supernatant was discarded. The obtained pellet was suspended in 10 mL of 50 mM Tris--HCl, pH 7.4 (assay buffer) containing the same amounts of protease inhibitors as described above, and the homogenate was pelleted by centrifugation (48,000× *g* for 15 min at 4 °C). The pellet was washed once with assay buffer and an additional centrifugation step was performed (48,000× *g* for 15 min at 4 °C). The resulting cell membrane pellet was suspended at a final concentration of 1 mg of protein/mL in assay buffer and used for the binding assays. The protein content of a 20 μL membrane suspension was measured by the Bradford method using the Bio-Rad Protein Assay reagent, according to the manufacturer's protocol, with bovine serum albumin (BSA) as the standard.

To determine the specific binding of \[^3^H\]-PK11195 to the human astrocyte membrane suspensions, equilibrium radioligand binding assays were performed essentially as previously described \[[@B46-ijms-17-01028],[@B87-ijms-17-01028]\]. Briefly, different aliquots of human astrocyte membranes (10--100 μg of proteins) were incubated with \[^3^H\]-PK11195 (1.5 nM) in the presence (non-specific binding) or absence (total binding) of unlabelled PK11195 (1 μM) in a final volume of 500 mL of assay buffer for 90 min at 0 °C. For the saturation experiments, aliquots of human astrocyte membranes (20 μg of proteins) were incubated with eight different concentrations of \[^3^H\]-PK11195 (0.5--30 nM) in duplicate using the conditions described above. In each assay, the final ethanol concentration in the incubation buffer was less than 1% and did not interfere with specific \[^3^H\]-PK11195 binding.

4.8. Statistical Analysis {#sec4dot8-ijms-17-01028}
-------------------------

The data are reported as the means ± SEM of at least three independent experiments. All statistical analyses were performed using GraphPad 5.0 Prism Software (GraphPad Software, La Jolla, CA, USA). One-way ANOVA with Bonferroni's post-test and Spearman's correlation analyses were used to assess the statistical significance of the data. A *p* value ≤ 0.05 was considered statistically significant.
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![Effects of the PIGA ligands on the Oxidative Metabolism Activity/Proliferation index in U87MG human glioma cells. U87MG cells were treated with different concentrations of the compounds (10 nM--1 µM) in serum-reduced media (1% fetal bovine serum (FBS)), and the \[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenol)-2-(4-sulfophenyl)-2*H*-tetrazolium, inner salt\] (MTS) assay was performed after 48 h of treatment. The data are expressed as percentages of the proliferative/oxidative metabolism activity index compared to the control (0.1% dimethyl sulfoxide (DMSO), a concentration that not interfered with the assay), which was set to 100%, and represent the means ± standard error of the mean (SEM) of three different experiments performed in duplicate. The statistical analysis was performed using one-way analysis of variance (ANOVA) and Bonferroni's post-test; \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001 vs. the control.](ijms-17-01028-g001){#ijms-17-01028-f001}

![Effects of the PIGA ligands on pregnenolone production. C6 glioma cells (**A**) and U87MG cells (**B**) were incubated with different PIGA ligands (40 µM) for 2 h at 37 °C. The pregnenolone amounts were quantified by a competitive enzyme-linked immunosorbent assay. The data are expressed as percentage of pregnenolone production compared to the control, which was set to 100%, and represent the means ± SEM of three different determinations performed in duplicate. The statistical analysis was performed using one-way ANOVA and Bonferroni's post-test; \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001 vs. the control.](ijms-17-01028-g002){#ijms-17-01028-f002}

![Spearman's correlation analyses of the Oxidative Metabolism Activity/Proliferation (OMAP) index and pregnenolone production in U87MG cells. The percentages of pregnenolone production obtained in the steroidogenesis experiments (U87MG cells were exposed to 40 µM PIGA ligand in saline medium for 2 h) were correlated to the OMAP indexes obtained in the metabolic experiments (U87MG cells were exposed to 1 µM PIGA ligand in serum-reduced medium for 48 h). The statistical analyses were performed using the Spearman *r* correlation, reporting a *p* \< 0.001.](ijms-17-01028-g003){#ijms-17-01028-f003}

![Influence of pregnenolone production on the U87MG OMAP index. U87MG cells were treated with different concentrations of PIGA ligands (1 nM--10 µM) in the absence or presence of AMG (50 µM) in serum-reduced media (1% FBS), and the viable cells were counted after 48 h of treatment using the MTS assay. The data are expressed as percentages of the OMAP index compared to the control, which was set to 100%, and represent the means ± SEM of three different experiments performed in duplicate. The statistical analysis was performed using one-way ANOVA and Bonferroni's post-test; \*\* *p* \< 0.01, \*\*\* *p* \< 0.001 vs. the control; \#\# *p* \< 0.01, \#\#\# *p* \< 0.001 vs. the respective treatment without [dl]{.smallcaps}-aminoglutethimide (AMG).](ijms-17-01028-g004){#ijms-17-01028-f004}

![In vitro response of the human astrocytes to the PIGA1138 and PK11195 treatments. (**A**) Human astrocytes were treated with different concentrations of PIGA1138 and PK11195 (10 nM--1 µM) in serum-reduced media (1% FBS), and the MTS assay was performed after 48 h of treatment; (**B**) Human astrocytes were treated with different concentrations of PIGA1138 and PK11195 (10 nM--1·µM) in complete medium and the MTS assay was performed after 48 h of treatment. The data are expressed as percentages of metabolic activity compared to the control, which was set to 100%, and represent the means ± SEM of three different experiments performed in duplicate. \*\* *p* \< 0.01, \*\*\* *p* \< 0.001 vs. the control.](ijms-17-01028-g005){#ijms-17-01028-f005}

ijms-17-01028-t001_Table 1

###### 

TSPO binding affinity of the compounds. The concentration of the tested compounds that inhibited \[^3^H\]PK11195 binding to rat kidney mitochondrial membranes (IC~50~) by 50% was determined using six concentrations of the displacers, each performed in triplicate. The *K*~i~ values are the means ± SEM of three determinations.

  ----------------------------- ----------------- ----------------- ------------------- ------------- -------------------------
  ![](ijms-17-01028-i001.jpg)   **Compound**      ***R*~1~**        ***R*~2~**          **Ar**        ***K*~i~** **(nM) ^a^**
  **PIGA1228**                  (CH~2~)~3~CH~3~   (CH~2~)~3~CH~3~   3-Thienyl           2.83 ± 0.30   
  **PIGA1248**                  (CH~2~)~5~CH~3~   (CH~2~)~5~CH~3~   3-Thienyl           0.89 ± 0.10   
  **PIGA1175**                  (CH~2~)~2~CH~3~   (CH~2~)~2~CH~3~   *p*-Biphenyl        0.53 ± 0.05   
  **PIGA1165**                  (CH~2~)~3~CH~3~   (CH~2~)~3~CH~3~   *p*-Biphenyl        5.50 ± 1.00   
  **PIGA1174**                  (CH~2~)~5~CH~3~   (CH~2~)~5~CH~3~   *p*-Biphenyl        1.84 ± 0.20   
  **PIGA1128**                  (CH~2~)~2~CH~3~   (CH~2~)~2~CH~3~   2-Naphthyl          0.30 ± 0.04   
  **PIGA1136**                  (CH~2~)~3~CH~3~   (CH~2~)~3~CH~3~   2-Naphthyl          0.53 ± 0.06   
  **PIGA1130**                  (CH~2~)~5~CH~3~   (CH~2~)~5~CH~3~   2-Naphthyl          0.52 ± 0.06   
  **PIGA1137**                  CH~3~             (CH~2~)~3~CH~3~   2-Naphthyl          0.56 ± 0.06   
  **PIGA1138**                  CH~3~             (CH~2~)~4~CH~3~   2-Naphthyl          0.37 ± 0.04   
  **PIGA1226**                  (CH~2~)~3~CH~3~   (CH~2~)~3~CH~3~   *p*-Methoxyphenyl   20.3 ± 2.21   
  **PIGA1244**                  (CH~2~)~5~CH~3~   (CH~2~)~5~CH~3~   *p*-Methoxyphenyl   4.04 ± 0.44   
  **PIGA1212** ^a^              (CH~2~)~2~CH~3~   (CH~2~)~2~CH~3~   *p*-Methylphenyl    5.50 ± 0.38   
  **PK 11195 ^b^**                                                                      9.3 ± 0.50    
  ----------------------------- ----------------- ----------------- ------------------- ------------- -------------------------

^a^ Data taken from ref. \[[@B52-ijms-17-01028]\]; ^b^ Data taken from ref. \[[@B51-ijms-17-01028]\].

ijms-17-01028-t002_Table 2

###### 

Pregnenolone production in C6 and U87MG cells. The data are expressed as percentage of pregnenolone production compared to the control, which was set to 100%, and represent the means ± SEM of three different determinations performed in duplicate. The statistical analysis was performed using one-way ANOVA and Bonferroni's post-test.

  Compounds      Pregnenolone Production in C6 cells (% ± SEM)   *p*       Pregnenolone Production in U87MG cells (% ± SEM)   *p*
  -------------- ----------------------------------------------- --------- -------------------------------------------------- ---------
  **PIGA1128**   148.4 ± 4.643                                   \<0.01    190.0 ± 8.356                                      \<0.001
  **PIGA1136**   164.0 ± 2.096                                   \<0.01    177.3 ± 7.963                                      \<0.001
  **PIGA1130**   155.0 ± 5.774                                   \<0.01    145.8 ± 3.393                                      \<0.01
  **PIGA1137**   208.0 ± 4.933                                   \<0.001   287.6 ± 11.98                                      \<0.001
  **PIGA1138**   245.0 ± 5.774                                   \<0.001   298.7 ± 10.14                                      \<0.001
  **PK 11195**   138.5 ± 9.717                                   \<0.05    143.8 ± 20.40                                      \<0.01
